The use of AI in medical treatment and diagnosis is rapidly picking up the pace. In fact, Brainomix, a renowned medical imaging entity, is one of the supporters of this revolutionary move. The company has carved a name for itself in using artificial intelligence (AI) for prompt treatment and diagnosis of stroke victims.
Brainomix was launched in 2010 as an Oxford University’s spin-out with a mission to become a worldwide leader in imaging software that helps in making medical decisions in neurology. The company consists of a lineup of experts including researchers, scientists, stroke neurologist, and clinicians. As such, Brainomix is strategically positioned to deal with the wide array of problems associated with stroke diagnosis and treatment.
Recently, Brainomix revealed that it had secured a £7 million investment to develop its technology to global scale. Parkwalk Advisors, university investment veterans, led the financing round for Brainomix’s venture. Some of the other investors that participated in the exercise include Oxford University Innovation Fund and Chimera Partners. The round also featured newcomers like Boehringer Ingelheim Venture Fund (BIVF), Boehringer Ingelheim’s corporate venture fund. The money raised from the round would aid Brainomix in globally commercializing its artificial intelligence software and imaging, leading to worldwide prominence.
Currently, Brainomix boasts a core software solution called e-ASPECTS, which utilizes AI technology in a bid to evaluate patient CT scans. Doing so, generates a standardized and rapid analysis of the image, causing clinical experts with vast experience to make consistent and backed medical decisions. The technology operates through the automation of the Alberta Stroke Programme Early CT Score (ASPECTS) technique, which has been clinically approved. The e-ASPECTS software will aid healthcare experts with differing skills to evaluate CT scans in a bid to make fast decisions for their patients. Furthermore, using e-ASPECTS has proven that it can improve stroke treatment results at a lower cost.
Dr. Michalis Papadakis, Brainomix’s chief executive officer, welcomed Boehringer Ingelheim Venture Fund to Brainomix’s team of investors. He added that Boehringer’s heritage and expertise in stroke would complement the existing investors’ knowledge in the medical condition. Michalis also acknowledged the growth of Brainomix from just a spinout of Oxford University to a worldwide market leader that has its stroke decision support and tools being used in various top stroke centers located in 16 nations globally. As a result, the investment is expected to help the company grow internationally and continuously boost its intelligent imaging software for both clinical trials and acute stroke care.
Alastair Kilgour of Parkwalk Advisors joined Dr. Michalis in welcoming Boehringer Ingelheim Venture Fund (BIVF) to Brainomix’s group of investors. He also said that Parkwalk looks forward to continuing assisting the management of Brainomix in maintaining its global leadership in artificial intelligent medical imaging, especially for stroke.
Frank Kalkbrenner, the managing director of BIVF, acknowledged Brainomix for being a cutting-edge technology entity that has superior expertise in developing innovative stroke care technologies. What’s more, he expressed his excitement on behalf of his company for the excellent opportunity to join the group of investors and accomplished management team of Brainomix. BIVF looks forward to collaborating with the company on revolutionary advancements in stroke care.